Researchers at Tel Aviv University (TAU) discovered a new factor in the pathology of Parkinson's disease, which in the future ...

Analysis suggests that the research and development of DMTs and non-motor therapies will diversify Parkinson's treatment ...

A team of researchers from the University of Barcelona and the Bellvitge Biomedical Research Institute (IDIBELL) has ...

Researchers at Tel Aviv University (TAU) discovered a new factor in the pathology of Parkinson's disease, which in the future ...

A team of researchers from the University of Barcelona and the Bellvitge Biomedical Research Institute (IDIBELL) has identified a potential biomarker of Parkinson's disease progression.

Israeli scientists have identified a promising new factor in the pathology of Parkinson’s disease that could pave the way for ...

GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...

Nir Giladi from TAU’s Faculty of Medical and Health Sciences and the Tel Aviv Sourasky Medical Center, as well as other researchers from TAU and the University of Haifa. The study was backed by the ...

The researchers note that, "despite the similarities, patients with these diseases have a different prognosis and do not ...

Oct. 18, 2024 -- The FDA has approved a new injectable treatment for adults with advanced Parkinson’s disease called Vyalev (also known as Produodopa). This new option is designed to help people ...

This year has seen several biopharma companies drop Alzheimer’s and Parkinson’s disease programs, but experts say plenty are ...

Early initiation of pimavanserin among patients with Parkinson disease psychosis were more likely to experience complete symptom resolution.